Lucentis is indicated in adults for: The treatment of neovascular (wet) age-related macular degeneration (AMD) The treatment of visual impairment due to choroidal neovascularisation (CNV) The treatment of visual impairment due to diabetic macular oedema (DME) The treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO)
CIMERLI — SANDOZ INC, approved 2024-05-21 (BLA761165).
20,521 reports across the top reactions. These are spontaneously reported events from the FDA Adverse Event Reporting System — they reflect reporting volume, not incidence or frequency, and a report does not mean the drug caused the event.